Total immunotherapy for Hodgkin lymphoma

Affiliations

¹ Department of Hematology, Rennes University Hospital, University of Rennes, INSERM U1236, Rennes, France; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
³ Department of Hematology, Hôpital Claude Huriez, Centre Hospitalier Regional Universitaire, Lille, France; Lille University Hospital, University of Lille, Lille F-59000, France. Electronic address: franck.morschhauser@chru-lille.fr.

Free article

Comment

Roch Houot et al. Lancet Haematol. 2020 Sep.

Free article

. 2020 Sep;7(9):e629-e630.

doi: 10.1016/S2352-3026(20)30220-9.

¹ Department of Hematology, Rennes University Hospital, University of Rennes, INSERM U1236, Rennes, France; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
³ Department of Hematology, Hôpital Claude Huriez, Centre Hospitalier Regional Universitaire, Lille, France; Lille University Hospital, University of Lille, Lille F-59000, France. Electronic address: franck.morschhauser@chru-lille.fr.

No abstract available

Comment on

Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.
Diefenbach CS, Hong F, Ambinder RF, Cohen JB, Robertson MJ, David KA, Advani RH, Fenske TS, Barta SK, Palmisiano ND, Svoboda J, Morgan DS, Karmali R, Sharon E, Streicher H, Kahl BS, Ansell SM. Diefenbach CS, et al. Lancet Haematol. 2020 Sep;7(9):e660-e670. doi: 10.1016/S2352-3026(20)30221-0. Lancet Haematol. 2020. PMID: 32853585 Free PMC article. Clinical Trial.